Ocuphire Pharma acquires Opus Genetics in all-stock transaction, to switch name
PremiumThe FlyOcuphire Pharma acquires Opus Genetics in all-stock transaction, to switch name
14d ago
Ocuphire Pharma trading halted, news pending
Premium
The Fly
Ocuphire Pharma trading halted, news pending
14d ago
Ocuphire Pharma announces publication of Phase 3 results of RYZUMVI
Premium
The Fly
Ocuphire Pharma announces publication of Phase 3 results of RYZUMVI
1M ago
Ocuphire Pharma price target lowered to $11 from $18 at JonesResearch
PremiumThe FlyOcuphire Pharma price target lowered to $11 from $18 at JonesResearch
3M ago
Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting
Premium
The Fly
Ocuphire Pharma to highlight APX3330 at ARVO SIG panel, ASRS meeting
4M ago
Ocuphire Pharma announces presentations on development of APX3330
Premium
The Fly
Ocuphire Pharma announces presentations on development of APX3330
5M ago
Ocuphire Pharma announces presentation on APX3330 at ARVO 2024
PremiumThe FlyOcuphire Pharma announces presentation on APX3330 at ARVO 2024
6M ago
OCUP Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
OCUP Earnings this Week: How Will it Perform?
6M ago
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
Premium
Company Announcements
Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100